Fluticasone-based inhaled corticosteroid treatment substantially changed airway microbiome diversity in patients with COPD, according to new data published in the American Journal of Respiratory and Critical Care Medicine.
“Inhaled corticosteroids . . . can change the microbial communities of airways of COPD patients, rendering them more susceptible for pneumonia,” Don D. Sin, MD, director and De Lazzari Family Chair at the Centre for Heart Lung Innovation, Canada Research Chair in COPD and professor of respiratory medicine, department of medicine at St. Paul’s Hospital, Vancouver, British Columbia, is quoted saying in Healio.
The study results according to the Healio report related to “reduced abundances of Pasteurellas, Pasteurellaceae and Haemophilus.” It also suggests that further studies are needed to determine “which bacterial organisms are responsible for keeping the microbiome airway healthy”.